Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls.
NSCLC
cfDNA
liquid biopsy
next generation sequencing
targeted therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Dec 2020
17 Dec 2020
Historique:
received:
11
11
2020
revised:
11
12
2020
accepted:
15
12
2020
entrez:
22
12
2020
pubmed:
23
12
2020
medline:
23
12
2020
Statut:
epublish
Résumé
Lung cancer (LC) is the main cause of death for cancer worldwide and non-small cell lung cancer (NSCLC) represents the most common histology. The discovery of genomic alterations in driver genes that offer the possibility of therapeutic intervention has completely changed the approach to the diagnosis and therapy of advanced NSCLC patients, and tumor molecular profiling has become mandatory for the choice of the most appropriate therapeutic strategy. However, in approximately 30% of NSCLC patients tumor tissue is inadequate for biomarker analysis. The development of highly sensitive next generation sequencing (NGS) technologies for the analysis of circulating cell-free DNA (cfDNA) is emerging as a valuable alternative to assess tumor molecular landscape in case of tissue unavailability. Additionally, cfDNA NGS testing can better recapitulate NSCLC heterogeneity as compared with tissue testing. In this review we describe the main advantages and limits of using NGS-based cfDNA analysis to guide the therapeutic decision-making process in advanced NSCLC patients, to monitor the response to therapy and to identify mechanisms of resistance early. Therefore, we provide evidence that the implementation of cfDNA NGS testing in clinical research and in the clinical practice can significantly improve precision medicine approaches in patients with advanced NSCLC.
Identifiants
pubmed: 33348595
pii: cancers12123804
doi: 10.3390/cancers12123804
pmc: PMC7766403
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Italian Ministry of Health
ID : Ricerca Corrente M4/2
Références
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
J Thorac Oncol. 2015 Nov;10(11):1553-9
pubmed: 26309190
Lung Cancer. 2019 Nov;137:1-6
pubmed: 31518912
EMBO Mol Med. 2018 Jun;10(6):
pubmed: 29848757
Nat Rev Clin Oncol. 2017 Sep;14(9):531-548
pubmed: 28252003
Cancer. 2020 Jul 15;126(14):3219-3228
pubmed: 32365229
Nat Med. 2019 Dec;25(12):1928-1937
pubmed: 31768066
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Cancers (Basel). 2019 Mar 10;11(3):
pubmed: 30857358
Science. 2020 Mar 27;367(6485):1449-1454
pubmed: 32217721
Ann Oncol. 2018 Jan 1;29(suppl_1):i10-i19
pubmed: 29462254
Sci Rep. 2018 Nov 19;8(1):17270
pubmed: 30451938
Oncotarget. 2016 Mar 15;7(11):12289-304
pubmed: 26802023
Oncotarget. 2017 Jun 6;8(23):38056-38060
pubmed: 28445137
Expert Opin Ther Targets. 2017 Feb;21(2):159-165
pubmed: 28002980
J Thorac Dis. 2019 Jan;11(Suppl 1):S71-S80
pubmed: 30775030
Cancer Discov. 2017 Dec;7(12):1394-1403
pubmed: 28899864
Future Oncol. 2015;11(11):1611-23
pubmed: 26043215
Expert Rev Anticancer Ther. 2018 Oct;18(10):1021-1030
pubmed: 30079781
PLoS One. 2018 Mar 16;13(3):e0194630
pubmed: 29547634
Cancers (Basel). 2015 Apr 30;7(2):763-83
pubmed: 25941796
J Thorac Oncol. 2020 Jul;15(7):1232-1239
pubmed: 32179180
Nat Rev Clin Oncol. 2018 Oct;15(10):639-650
pubmed: 30050094
Expert Rev Anticancer Ther. 2019 Jan;19(1):19-28
pubmed: 30462523
Lung Cancer. 2020 Sep;147:123-129
pubmed: 32693293
Cancer Treat Rev. 2020 Feb;83:101951
pubmed: 31874446
Med Oncol. 2017 Jun;34(6):105
pubmed: 28444624
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
Ther Adv Med Oncol. 2020 Jul 3;12:1758835920937902
pubmed: 32670423
Lung Cancer. 2019 Aug;134:225-232
pubmed: 31319985
Curr Pharm Des. 2014;20(24):3883-93
pubmed: 24138718
Nat Rev Clin Oncol. 2013 Aug;10(8):472-84
pubmed: 23836314
JAMA Oncol. 2018 May 1;4(5):739-742
pubmed: 29596544
Clin Cancer Res. 2018 Aug 1;24(15):3539-3549
pubmed: 29691297
Cancer Med. 2019 Dec;8(18):7669-7678
pubmed: 31692284
Ann Oncol. 2017 Apr 1;28(4):784-790
pubmed: 28104619
Ann Oncol. 2018 Jan 1;29(suppl_1):i38-i46
pubmed: 29462257
Nat Med. 2015 Jun;21(6):560-2
pubmed: 25939061
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
Cancer Treat Rev. 2013 Aug;39(5):489-97
pubmed: 23022519
PLoS One. 2015 Oct 16;10(10):e0140712
pubmed: 26474073
N Engl J Med. 2020 Sep 3;383(10):944-957
pubmed: 32877583
Clin Cancer Res. 2019 Nov 15;25(22):6644-6652
pubmed: 31439584
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Am Soc Clin Oncol Educ Book. 2019 Jan;39:e187-e197
pubmed: 31099642
Hum Mutat. 2015 Sep;36(9):903-14
pubmed: 26110913
Nat Med. 2016 Jan;22(1):105-13
pubmed: 26618723
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Ann Oncol. 2018 Apr 1;29(4):1049-1055
pubmed: 29325035
Clin Cancer Res. 2018 Apr 15;24(8):1872-1880
pubmed: 29330207
Lung Cancer. 2018 Oct;124:110-116
pubmed: 30268447
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
Clin Cancer Res. 2019 Aug 1;25(15):4691-4700
pubmed: 30988079
Transl Lung Cancer Res. 2020 Feb;9(1):61-70
pubmed: 32206554
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188363
pubmed: 32275933
Nat Commun. 2016 Jun 10;7:11815
pubmed: 27283993
Clin Cancer Res. 2017 Sep 1;23(17):5101-5111
pubmed: 28539465
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Lancet Respir Med. 2018 Feb;6(2):107-116
pubmed: 29249325
Nat Med. 2014 May;20(5):548-54
pubmed: 24705333
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Oncotarget. 2016 Oct 11;7(41):66595-66605
pubmed: 27448974
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
N Engl J Med. 2005 Feb 24;352(8):786-92
pubmed: 15728811
Ann Oncol. 2015 Aug;26(8):1715-22
pubmed: 25851626
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
PLoS One. 2019 Dec 20;14(12):e0226853
pubmed: 31860648
Cell Death Dis. 2019 Jul 11;10(7):534
pubmed: 31296838
Sci Transl Med. 2017 Aug 16;9(403):
pubmed: 28814544
Clin Cancer Res. 2019 Aug 1;25(15):4592-4602
pubmed: 30824587
Ann Oncol. 2019 May;30(5):863-870
pubmed: 31987360
Mol Med. 2019 Apr 27;25(1):15
pubmed: 31029076
Clin Lung Cancer. 2018 Nov;19(6):518-530.e7
pubmed: 30279111
PLoS One. 2020 Jun 11;15(6):e0234302
pubmed: 32525942
N Engl J Med. 2020 Aug 27;383(9):813-824
pubmed: 32846060
J Thorac Oncol. 2016 Oct;11(10):1690-700
pubmed: 27468937
Nature. 2017 Apr 26;545(7655):446-451
pubmed: 28445469
Transl Lung Cancer Res. 2018 Dec;7(6):668-677
pubmed: 30505711
Arch Pathol Lab Med. 2016 Apr;140(4):341-4
pubmed: 26780537
Lung Cancer. 2015 Dec;90(3):509-15
pubmed: 26494259
Transl Lung Cancer Res. 2020 Apr;9(2):366-372
pubmed: 32420077
Clin Cancer Res. 2015 May 15;21(10):2379-87
pubmed: 25688157
Nat Genet. 2017 Dec;49(12):1693-1704
pubmed: 29106415
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3178-9
pubmed: 25733911
Nat Biotechnol. 2016 May;34(5):547-555
pubmed: 27018799
Nat Commun. 2018 May 24;9(1):2054
pubmed: 29799009
J Thorac Oncol. 2019 May;14(5):816-824
pubmed: 30664990
JAMA Oncol. 2019 Feb 1;5(2):173-180
pubmed: 30325992
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Sci Transl Med. 2012 May 30;4(136):136ra68
pubmed: 22649089
Oncotarget. 2017 Feb 14;8(7):12501-12516
pubmed: 27980215
Mol Cancer. 2018 Feb 19;17(1):38
pubmed: 29455650
Front Oncol. 2019 Apr 24;9:317
pubmed: 31069172